InnoPharmax, Inc. Statistics
InnoPharmax, Inc. (4172) Stock Statistics & Valuation Metrics
Total Valuation
InnoPharmax, Inc. has a market cap or net worth of TWD 1.06B. The enterprise value is ―.
- Market Cap
- TWD 1.06B
- Enterprise Value
- ―
Share Statistics
InnoPharmax, Inc. has 117,775,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 117,775,500
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
InnoPharmax, Inc.’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -39.92%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -39.92%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 2.09M
- Profits Per Employee
- -5.59M
- Employee Count
- 33
- Asset Turnover
- 0.15
- Inventory Turnover
- 4.02
Valuation Ratios
The current PE Ratio of InnoPharmax, Inc. is -4.95. InnoPharmax, Inc.’s PEG ratio is 0.07.
- PE Ratio
- -4.95
- PS Ratio
- 15.89
- PB Ratio
- 1.99
- Price to FCF
- -18.30
- Price to Operating Cash Flow
- -7.00
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, InnoPharmax, Inc. had revenue of 68.99M and earned -184.40M in profits. Earnings per share was -1.70.
- Revenue
- 68.99M
- Gross Profit
- 3.51M
- Operating Income
- -171.76M
- Pretax Income
- -180.89M
- Net Income
- -184.40M
- EBITDA
- -165.44M
- Earnings Per Share (EPS)
- -1.70
Cash Flow
In the last 12 months, operating cash flow was -150.79M and capital expenditures 92.21M, giving a free cash flow of -58.57M billion.
- Operating Cash Flow
- -150.79M
- Free Cash Flow
- -58.57M
- Free Cash Flow per Share
- -0.50
Dividends & Yields
InnoPharmax, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.29%
- Earnings Yield
- -18.65%
Stock Price Statistics
- Beta
- 0.12
- 52-Week Price Change
- -49.72%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 34.67
- Average Volume (3m)
- 193.58K
Financial Position
InnoPharmax, Inc. as a current ratio of 3.52, with Debt / Equity ratio of 2.64%
- Current Ratio
- 3.52
- Quick Ratio
- 3.20
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.52
- Interest Coverage Ratio
- -448.46
Taxes
In the past 12 months, InnoPharmax, Inc. has paid 3.51M in taxes.
- Income Tax
- 3.51M
- Effective Tax Rate
- -0.02
Enterprise Valuation
InnoPharmax, Inc. EV to EBITDA ratio is -5.01, with an EV/FCF ratio of -15.95.
- EV to Sales
- 13.85
- EV to EBITDA
- -5.01
- EV to Free Cash Flow
- -15.95
- EV to Operating Cash Flow
- -6.20
Balance Sheet
InnoPharmax, Inc. has TWD 263.77M in cash and marketable securities with TWD 11.80M in debt, giving a net cash position of TWD 251.97M billion.
- Cash & Marketable Securities
- TWD 263.77M
- Total Debt
- TWD 11.80M
- Net Cash
- TWD 251.97M
- Net Cash Per Share
- TWD 2.14
- Tangible Book Value Per Share
- TWD 4.42
Margins
Gross margin is 10.41%, with operating margin of -285.80%, and net profit margin of -301.84%.
- Gross Margin
- 10.41%
- Operating Margin
- -285.80%
- Pretax Margin
- -296.64%
- Net Profit Margin
- -301.84%
- EBITDA Margin
- -276.61%
- EBIT Margin
- -285.80%
Analyst Forecast
The average price target for InnoPharmax, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 20.97%
- EPS Growth Forecast
- -78.23%
